Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

By afschroeder • May 17, 2026

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb). 2026 May 16. doi: 10.1007/s13555-026-01738-6. Epub ahead of print. PMID: 42143206.

Tags: Dermatology, DLQI, Oral therapy, PASI, patient-reported outcomes, plaque psoriasis, psoriasis, Publications, Skin clearance, TYK2 inhibitor, Zasocitinib

Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical Trial

Armstrong AW, Roberts AM, Kostandy G, Choudhury F, Yee D, Luu M, Jones ME, Alizadeh ER, Cotliar J, Chren MM, Gelfand JM, Cockburn M, Doctor[...]

Alopecia Areata Is Associated with Increased Risk of Infertility in a Retrospective Cohort Study Using TriNetX

Podolsky AS, Goh C, Lipner SR. Alopecia Areata Is Associated with Increased Risk of Infertility in a Retrospective Cohort Study Using TriNetX. Skin Appendage Disord.[...]

Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis

Bchiri S, Bahrini K, Teles RMB, Alaya AB, Kamel HE, West J, Rategh K, Bouzekri A, Bousalem E, Ouni R, Fassatoui M, Mardassi H, Dekhil[...]